BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 24976932)

  • 1. Neuroimaging in Huntington's disease.
    Niccolini F; Politis M
    World J Radiol; 2014 Jun; 6(6):301-12. PubMed ID: 24976932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Imaging Markers to Track Huntington's Disease Pathology.
    Wilson H; De Micco R; Niccolini F; Politis M
    Front Neurol; 2017; 8():11. PubMed ID: 28194132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Magnetic Resonance Imaging in Huntington's Disease.
    Wilson H; Dervenoulas G; Politis M
    Int Rev Neurobiol; 2018; 142():335-380. PubMed ID: 30409258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status of PET imaging in Huntington's disease.
    Pagano G; Niccolini F; Politis M
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1171-82. PubMed ID: 26899245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Choreas.
    Fazio P; Paucar M; Svenningsson P; Varrone A
    Curr Neurol Neurosci Rep; 2018 Oct; 18(12):85. PubMed ID: 30291526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Imaging in Huntington's Disease.
    Wilson H; Politis M
    Int Rev Neurobiol; 2018; 142():289-333. PubMed ID: 30409256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET Imaging in Huntington's Disease.
    Roussakis AA; Piccini P
    J Huntingtons Dis; 2015; 4(4):287-96. PubMed ID: 26683130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.
    Niccolini F; Haider S; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Piccini P; Kapur S; Rabiner EA; Gunn RN; Tabrizi SJ; Politis M
    Brain; 2015 Oct; 138(Pt 10):3016-29. PubMed ID: 26198591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early grey matter changes in structural covariance networks in Huntington's disease.
    Coppen EM; van der Grond J; Hafkemeijer A; Rombouts SA; Roos RA
    Neuroimage Clin; 2016; 12():806-814. PubMed ID: 27830113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of Huntington's Disease: An Emphasis on Molecular Pathways and Prevention by Natural Remedies.
    Irfan Z; Khanam S; Karmakar V; Firdous SM; El Khier BSIA; Khan I; Rehman MU; Khan A
    Brain Sci; 2022 Oct; 12(10):. PubMed ID: 36291322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study.
    Politis M; Pavese N; Tai YF; Kiferle L; Mason SL; Brooks DJ; Tabrizi SJ; Barker RA; Piccini P
    Hum Brain Mapp; 2011 Feb; 32(2):258-70. PubMed ID: 21229614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hybrid 2-[18F] FDG PET/MRI in premanifest Huntington's disease gene-expansion carriers: The significance of partial volume correction.
    Hellem MNN; Vinther-Jensen T; Anderberg L; Budtz-Jørgensen E; Hjermind LE; Larsen VA; Nielsen JE; Law I
    PLoS One; 2021; 16(6):e0252683. PubMed ID: 34115782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Multidimensional Brain Imaging in Huntington's Disease Animal Models.
    Flament J; Hantraye P; Valette J
    Methods Mol Biol; 2018; 1780():285-301. PubMed ID: 29856025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal hypometabolism in premanifest and manifest Huntington's disease patients.
    López-Mora DA; Camacho V; Pérez-Pérez J; Martínez-Horta S; Fernández A; Sampedro F; Montes A; Lozano-Martínez GA; Gómez-Anson B; Kulisevsky J; Carrió I
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2183-2189. PubMed ID: 27349245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease.
    Sampedro F; Martínez-Horta S; Perez-Perez J; Horta-Barba A; Lopez-Mora DA; Camacho V; Fernández-León A; Gomez-Anson B; Carrió I; Kulisevsky J
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1111-1116. PubMed ID: 30627816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic network as a progression biomarker of premanifest Huntington's disease.
    Tang CC; Feigin A; Ma Y; Habeck C; Paulsen JS; Leenders KL; Teune LK; van Oostrom JC; Guttman M; Dhawan V; Eidelberg D
    J Clin Invest; 2013 Sep; 123(9):4076-88. PubMed ID: 23985564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basal ganglia-cortical structural connectivity in Huntington's disease.
    Novak MJ; Seunarine KK; Gibbard CR; McColgan P; Draganski B; Friston K; Clark CA; Tabrizi SJ
    Hum Brain Mapp; 2015 May; 36(5):1728-40. PubMed ID: 25640796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic modifiers of Huntington's disease.
    Gusella JF; MacDonald ME; Lee JM
    Mov Disord; 2014 Sep; 29(11):1359-65. PubMed ID: 25154728
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.